
美国当局指控一家加拿大公司的两名高管长期实施计划,非法将处方药进口到美国,法庭记录显示。
U.S. authorities are accusing the two top officials of a Canadian company of operating a long-running scheme to illegally import prescription drugs into the U.S., according to court records.
该公司CANARX的财务总监兼董事John Thomas Howard于周日因走私和共谋罪名被捕。记录显示,他的兄弟、CANARX总裁兼董事Bob Howard也在调查中被通缉。
John Thomas Howard, treasurer and a director of the company, CANARX, was arrested Sunday on smuggling and conspiracy charges. His brother Bob Howard, CANARX president and director, is wanted in the investigation, according to records.
CNBC去年的调查报道“RiskyRX”曾曝光CANARX。报道揭示,随着药价飙升,该公司及其他被称为“替代资金计划”(AFP)的机构正在美国变得更加普遍。
CANARX was featured in a CNBC investigation "RiskyRX" last year that revealed how the company and others known as alternative funding programs, or AFPs, are becoming more pervasive around the U.S. as drug costs skyrocket.
法庭记录显示,CANARX财务总监兼董事John Thomas Howard因走私和共谋罪名于周日被捕。
John Thomas Howard, treasurer and a director of the company, CANARX, was arrested Sunday on smuggling and conspiracy charges, according to the records.
根据美国食品药品监督管理局刑事调查办公室特别探员Dustin Dobbs的宣誓书,他的兄弟、CANARX总裁兼董事Bob Howard也在联邦调查中被通缉。他尚未被羁押。
Bob Howard, his brother, who is president and a director of CANARX, is also wanted in the federal investigation, according to an affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations. He has not yet been taken into custody.
逮捕令称,除共谋和走私外,John Thomas Howard还被指控将贴错标签的药品引入州际贸易和非法进口药品。目前未提交认罪答辩。
Besides conspiracy and smuggling, the arrest warrant said John Thomas Howard was charged with introducing misbranded drugs into interstate commerce and illegal drug importation. No plea has been filed.
CNBC去年的调查报道曝光了CANARX。报道揭示,随着药价飙升,该公司及其他被称为“替代资金计划”(AFP)的机构正在美国变得更加普遍。调查发现,这些公司通过向私营和公共雇主以更实惠的价格提供高成本专科药物,已渗透进美国医疗体系。在某些情况下,雇主要求员工必须使用AFP。
CANARX was featured in a CNBC investigation last year that revealed how the company and others known as alternative funding programs, or AFPs, are becoming more pervasive around the U.S. as drug costs skyrocket. The investigation found these companies have penetrated the country's healthcare system by offering high-cost specialty drugs at more affordable prices through private and public employers. In some cases, employers are requiring their staff to use an AFP.
AFP 通常在海外获取药物并直接邮寄给患者,联邦当局称这种做法属于非法,且存在安全风险。CNBC 追踪了药物从海外经由一条未经生产这些药物的制药公司授权的供应链流入美国的路径。
AFPs often obtain the medications overseas and ship them directly to patients, a practice that federal authorities have said is illegal and poses safety risks. CNBC traced the trail of drugs from abroad to the U.S. via a supply chain that the pharmaceutical companies producing the medications have not authorized.
在其网站上,成立于 2002 年、总部位于加拿大安大略省温莎市的 CANARX 将其业务描述为美国首家国际处方药提供商,以及行业内最安全的此类项目。该公司称其药物来源于加拿大、英国、澳大利亚和新西兰。
On its website, CANARX, founded in 2002 and based in Windsor, Ontario, Canada, described its business as the first international prescription provider for the U.S. and the safest such program in the industry. The company said it sources its medications from Canada, the United Kingdom, Australia and New Zealand.
但宣誓书称,FDA 的调查发现“有合理理由相信(CANARX)非法进口或导致处方药被非法进口到美国……”。宣誓书未具体说明该机构认为哪些药物被非法进口。刑事起诉书涵盖的时间段为 2017 年 2 月 22 日至 2026 年 4 月 15 日。
But the affidavit said that the FDA's investigation found "there is probable cause to believe that (CANARX) illegally imported or caused the illegal importation of prescription drugs into the United States…" The affidavit does not specify which medications the agency believes were illegally imported. The criminal complaint covers the period from Feb. 22, 2017 through April 15, 2026.
该公司总法律顾问约瑟夫·莫里斯在给 CNBC 的声明中表示:“霍华德夫妇否认针对他们的所有指控,将进行强有力的辩护,并期待在法庭上获得平反。”该公司已接受 FDA 多年的审查。根据 CNBC 获得的一封发给患者的电子邮件,2023 年,该机构扣押了 CANARX 邮寄的药物,称这些药物可能属于错误标识和假冒产品。
The company's general counsel, Joseph Morris, told CNBC in a statement: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court." The company has been under FDA scrutiny for several years. In 2023, the agency seized medication being shipped by CANARX that it says was potentially misbranded and counterfeit, according to an email sent to a patient that was obtained by CNBC.
2019 年,FDA 曾向该公司发出警告信,称其“以一种用未经批准的药物替代美国医疗服务提供者开具的 FDA 批准药物的方式运营”。针对该警告,莫里斯辩称 CANARX 并未误导患者,但同意公司停止进口需要由医生给药的药物。
And in 2019, the FDA sent a warning letter to the company, saying it was operating "in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs." Morris, in response to that warning, argued CANARX was not misleading patients, but agreed for the company to stop importing drugs that need to be administered by a doctor.
作为 CNBC 调查的一部分,Morris 在去年的一次采访中表示,运往美国患者的药品来自监管严格的国家。他称 CANARX 合法经营。
In an interview as part of the CNBC investigation, Morris said last year that the medicines shipped to U.S. patients come from highly regulated countries. He said CANARX was operating legally.
美国联邦药房(AFPs)面临的核心问题是,为个人用途进口处方药到美国是否合法。美国食品药品监督管理局(FDA)允许美国人在某些情况下为个人用途进口药品,前提是该药品在国内无法买到。AFPs 正是以此为基础,建立了直接向患者邮寄药品的模式。
The central question for AFPs is the legality of importing prescription drugs into the U.S. for personalized use. The FDA allows Americans to import medications for individual use in some cases if the drug is not available domestically. That is the basis on which the AFPs built their models for shipping medicines directly to patients.
但 FDA 一位发言人去年告诉 CNBC:“在大多数情况下,个人不能从其他国家进口处方药到美国……作为 FDA 批准药品的替代品。”在另一起正在进行的民事诉讼中,吉利德科学公司指控 CANARX 及其他公司非法进口其治疗 HIV 的药物 Biktarvy。
But an FDA spokesperson told CNBC last year that "in most circumstances, a person cannot import prescription drugs from other countries into the U.S. ... as substitutes for FDA-approved drugs." In a separate civil lawsuit that is pending, Gilead Sciences accused CANARX and other companies of illegally importing Biktarvy, its medication to treat HIV.
吉利德一位发言人周三在给 CNBC 的声明中表示,该公司“已采取强有力的法律行动,以保护患者和美国药品供应链的完整性。我们欢迎政府努力追究那些可能使患者面临风险之人的责任。”CANARX 尚未对吉利德的诉讼作出回应。
In a statement to CNBC on Wednesday, a Gilead spokesperson said the company "has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain. We welcome the government's efforts to hold accountable those whose conduct may put patients at risk." CANARX has not responded to the Gilead lawsuit.